Lyell Immunopharma, Inc.
LYELLyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation autologous CAR T-cell therapies for hematologic malignancies and solid tumors.
Table of contents
Earnings
Next report
Aug 11, 2026 (In 1 week)Competitors
By market cap
By revenue growth
Profile
Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation autologous CAR T-cell therapies for hematologic malignancies and solid tumors. The company utilizes proprietary technologies and manufacturing protocols to engineer T cells that resist exhaustion and maintain stemlike features, aiming to provide durable clinical responses where first-generation therapies fail.
A late-stage clinical player specializing in T-cell exhaustion resistance and dual-targeting CAR T constructs to overcome limitations of first-generation cell therapies.
Questions, answered.
- What is Lyell Immunopharma, Inc.'s market cap?
- Lyell Immunopharma, Inc. (LYEL) has a market capitalization of $317.6M and trades on NASDAQ.
- Who are Lyell Immunopharma, Inc.'s competitors?
- Lyell Immunopharma, Inc.'s key competitors include Gilead Sciences, Bristol-Myers Squibb, Tempest Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Lyell Immunopharma, Inc. partner with?
- Lyell Immunopharma, Inc.'s notable partners include Innovative Cellular Therapeutics Holdings Limited, Innovative Cellular Therapeutics, Inc..
- Where is Lyell Immunopharma, Inc. headquartered?
- Lyell Immunopharma, Inc. is headquartered in United States of America and employs approximately 224 people. It has been publicly traded since 2021.